Stock comparison
Pharming Group N.V.
United Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
PHAR
Pharming Group N.V.
Market cap
$889.88M
Sector
Healthcare
UTHR
United Therapeutics
Market cap
$24.13B
Sector
Healthcare
Overall winner
United Therapeutics UTHR
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | PHAR | UTHR | Winner |
|---|---|---|---|
| Warren Buffett | 37D | 71B | UTHR |
| Benjamin Graham | 67D | 76B | UTHR |
| Philip Fisher | 43D | 76B | UTHR |
| Peter Lynch | 25F | 62C | UTHR |
| Joel Greenblatt | 44D | 46D | UTHR |
| Charlie Munger | 34F | 64C | UTHR |
| Terry Smith | 41D | 64C | UTHR |
Side-by-side metrics
| Metric | PHAR | UTHR |
|---|---|---|
| Market cap | $889.88M | $24.13B |
| P/E (TTM) | 77.6x | 19.2x |
| EV/EBIT | 50.7x | 15.2x |
| ROIC (TTM) | 3.76% | 18.81% |
| Gross margin | 88.12% | 86.58% |
| Net margin | 3.37% | 40.61% |
| Revenue CAGR 5y | 17.35% | 17.22% |
| EPS CAGR 5y | -33.13% | 29.84% |
| Debt / Equity | 0.4x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
PHAR leads on
No clear edges - the other side wins or ties on every measured metric.
UTHR leads on
- EPS CAGR 5y29.84%vs -33.13%+190%
- Debt / Equity-vs 0.4x+100%
- Market cap$24.13Bvs $889.88M+96%
- Net margin40.61%vs 3.37%+92%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.